Which company produces Mirikizumab?

Mirikizumab (Mirikizumab)-Omvoh is a humanized IgG4 monoclonal antibody mainly used to treat moderately to severely active ulcerative colitis. The drug is developed and manufactured by Eli Lilly and Company. Founded in 1876, Eli Lilly and Company is one of the world's leading pharmaceutical companies, developing innovative treatments to address unmet medical needs.

Milizumab has demonstrated good efficacy and safety in preclinical experiments and clinical trials. By selectively binding to the p19 subunit of IL-23, militizumab inhibits the interaction of IL-23 with its receptor, thereby reducing the release of pro-inflammatory cytokines and chemokines. This mechanism makes militizumab show good potential in the treatment of diseases related to the immune system, especially in the field of inflammatory bowel disease.

The development process of Militizumab began with in-depth research on the biological properties ofIL-23. As understanding of this cytokine's role in mucosal inflammation increases, researchers have discovered that intervention targeting IL-23 may improve symptoms of many chronic inflammatory diseases. In order to promote research in this direction, Eli Lilly has invested a lot of resources in related drug development.

In clinical trials, militizumab has shown good therapeutic effects, and many study results have shown that patients treated with militizumab have significant improvements in clinical remission rates and clinical response rates. In addition, the safety of militizumab has been relatively well evaluated, and its side effects are generally mild and manageable. These advantages make militizumab an effective treatment option for patients with inflammatory bowel disease.

Reference materials:https://en.wikipedia.org/wiki/Mirikizumab